In a ground-breaking development, Apollo Cancer Centres (ACCs) has emerged as the first private hospital group in India to have successfully complete CAR-T cell programme and to further augment it, the group will now provide access to ‘Made in India’ CAR-T cell therapy, beginning with NexCAR19 (Actalycabtagene autoleucel), for the treatment of B-cell lymphomas and B-acute lymphoblastic leukaemia in patients aged 15 years and above. 

CAR-T cell therapies have gained global recognition for their unparalleled success in transforming the lives of patients with challenging B-cell malignancies. Having treated over 25,000 patients worldwide, have benefited from this therapeutic model.

Dr Shisir Seth, Senior Consultant – Haematology, ACC, Delhi, said, "The successful treatment of three patients using CAR-T Cell therapy at the commercial level, represents a significant leap forward in our fight against B-cell lymphomas and acute lymphoblastic leukaemia. These cases highlight the efficacy and potential of this transformative therapy in providing new hope for patients facing these challenging conditions."

Sharing insights into the success of the programme, he further added, "Having successfully treated patients with imported drugs, we are now poised to treat them with the indigenously built therapy.”

Image caption- Dr Shisir Seth, Senior Consultant (Left), Dr Amita Mahajan, Senior Consultant - Paediatric Oncology & Haematology (Centre), P. Shivakumar, CEO, ACC Delhi (Right)